Leading-edge Manufacturing Technology, Immune Modulation Technology, Core Treatment Technology
- Intermediate crystallization Technology, Massive production technology with high purity & yield
- Technical barriers equal to those of material patents
Modulation Technology of Cytokine/Chemokine Release
- Modulation of IL-4, IL-6 release
- Modulation of CXCL2/8, CCL26 release
Modulation Technology of Immune Cell Migration and Inflammatory Reaction
- Modulation of neutrophil/ eosinophil migration
- Modulation of Transcription factor STAT3, STAT6
Global Phase 2 Clinical Trials
- Development of First-in-Class RA treatment
- Chemoradiation therapy induced oral mucositis & ARS through Orphan Drug Designation or Fast Track Designation
- Development of oral RA treatment with superior efficacy against Pfizer’s Xeljanz
- Development of first-in-class sepsis treatment in the market without competing drug
- Development of treatment for psoriasis, asthma and atopic dermatitis
Mechanism of Action
Mechanism of action of EC-18: EC-18 promotes the removal of DAMP and PAMP in a short period of time, thus inhibiting the continuous release of neutrophils from blood vessel, excessive infiltration of immune cells and excessive release of cytokines in inflammatory tissues and infection site.
Research Papers and Articles
PLAG (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol) ameliorates arthritic joints through reducing neutrophil infiltration mediated by IL-6/STAT3 and MIP-2 activation. Oncotarget 8(57):96636-96648, 2017.
The ameliorating effect of 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol on scopolamine-induced memory impairment via acetylcholinesterase inhibition and LTP activation. Behavioural Brain Research 324:58-65.
Protective effect of EC-18, a synthetic monoacetyldiglyceride on lung inflammation in a murine model induced by cigarette smoke and lipopolysaccharide. International Immunopharmacology: 30: 62-68, 2016Effect of 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol on immune functions in healthy adults in a randomized controlled trial. Immune Network, 15(3):150-60, 2015
EC-18, a synthetic monoacetyldiglyceride (1-palmitoyl-2-linoleoyl-3-acetylglycerol), attenuates the asthmatic response in an aluminum hydroxide/ovalbumin-induced model of asthma. International immunopharmacology 21;18(1):116-23, 2014.